Compare AbCellera Biologics Inc (ABCL) vs TotalEnergies SE (TTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs TotalEnergies SE — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while TotalEnergies SE trades at $78.7 (market cap $171.68B). The key difference: TotalEnergies SE is far larger — about 73.1× AbCellera Biologics Inc's market cap, and TotalEnergies SE pays a 5.41% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TTE | |
|---|---|---|
Market Cap | $2.35B | $171.68B |
Sector | Health | Energy |
52-Week High | $8.12 | $93.60 |
52-Week Low | $2.78 | $57.39 |
Enterprise Value | $1.99B | $205.82B |
Dividend Yield | — | 5.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
TotalEnergies (TTE) trades at $77.96, up 1.66% with a bearish technical signal despite recent earnings beat. The stock shows attractive valuation with P/E of 11.32 and P/S of 0.91, supported by stable dividends. Revenue declined to $182.34B in 2025 but net margins improved to 8.2%. Recent developments include new exploration contracts and strategic divestments, while cash flow trends show recovery with 2026 projection of $2.9B net cash flow.
Outlook remains cautiously optimistic given strong analyst buy ratings (57.58%) and value metrics, though bearish technicals and revenue declines pose near-term risks. The company's strategic moves in gas fields and emissions technology provide growth avenues, but regulatory pressures and oil price volatility require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
